Arima Genomics Introduces Aventa Lymphoma Test to Resolve Diagnostic Uncertainty in B- and T-Cell Lymphomas

Audio By Carbonatix

CARLSBAD, Calif.--(BUSINESS WIRE)--Sep 3, 2025--

Arima Genomics, Inc., a company leveraging whole-genome sequence and structure information to provide comprehensive cancer therapy selection insights, today announced the broad commercial launch of the Aventa Lymphoma test at the Society of Hematologic Oncology (SOHO 2025) meeting in Houston, Texas.

Offered through the CLIA-certified laboratory of the company’s Aventa clinical testing service, this ultra-sensitive, whole-genome test reports on gene fusions and rearrangements for 417 genes in B- and T-cell lymphomas, uncovering fusions and rearrangements that routine fluorescent in situ hybridization (FISH) panels frequently overlook and eliminating diagnostic ambiguity.

“Adopting a comprehensive solution like the Aventa Lymphoma test means we have a better chance of identifying rearrangements critical for accurate classification of lymphomas and optimal patient management,” said Russell Ryan, M.D., Assistant Professor of Pathology, University of Michigan Medical School. “Through the early access program, I had several challenging cases where the Aventa Lymphoma test identified unexpected variants that we confirmed with orthogonal testing, allowing us to make more specific diagnoses and direct patients’ ultimate treatment plans more appropriately.”

Lymphoma encompasses many distinct subtypes, and rearrangements of specific genes play a decisive role in classification, prognosis, and treatment selection. The current gold standard for detecting these rearrangements, FISH, is inherently target-limited: probes are run sequentially—consuming tissue and time—and success hinges on correctly choosing which genes to interrogate based on an initial diagnosis. FISH probes for rare types of lymphoma are not widely available. Even when the relevant genes are probed, cryptic breakpoints or atypical partners can lead to false negative results that conflict with other clinical evidence, leaving physicians without clear answers.

The Aventa Lymphoma test closes these gaps by leveraging Arima’s proximity-ligation DNA sequencing technology to assess the entire genome in a single assay. The need to predict which targets to test is eliminated, and rearrangements are captured regardless of breakpoint location or fusion partner. This whole-genome approach conserves tissue, shortens the diagnostic workflow, and provides a comprehensive tumor profile that can resolve cases where FISH results are ambiguous or inconclusive.

“The Aventa Lymphoma test can uncover gene fusions and rearrangements that may be missed by traditional FISH testing, ensuring clinically significant abnormalities are not overlooked. This transformative tool enhances patient care,” said Ying Zou, M.D., Ph.D., Director of Cancer Cytogenetic Laboratory, Cytogenomic Research Core and Associate Director of Molecular Diagnostics Laboratory at Johns Hopkins University. “In lymphomas exhibiting atypical FISH signal patterns across multiple biomarkers, the Aventa Lymphoma test identified actionable genetic alterations, significantly enhancing diagnostic precision, subtype classification, prognostic evaluation, and tailored treatment strategies.”

Following a successful soft launch earlier this year—and building on the 2023 launch of the Aventa FusionPlus solid tumor assay—Arima has secured Proprietary Laboratory Analysis (PLA) code 0592U from the American Medical Association (AMA) for Aventa Lymphoma.

“Our goal is to reduce blind spots in lymphoma diagnosis by offering an ultra-sensitive test that uncovers the full spectrum of clinically meaningful rearrangements—whether or not they are initially considered,” said Chris Roberts, Chief Product Officer for Arima Genomics and Executive Director for the Aventa clinical testing service. “With the Aventa Lymphoma test, physicians can resolve puzzling cases quickly and make informed treatment decisions without juggling multiple assays. We believe this approach complements existing pathology methods and leads to more precise patient management.”

To learn more, please visit us at booth #120 at SOHO 2025 or view the test website https://aventatest.com.

About Arima Genomics

Arima Genomics is redefining cancer diagnostics using whole-genome sequence and structure information. Arima’s assays enable a new era of comprehensive, clinically actionable therapy selection insights. The company serves oncologists through its CLIA-certified Aventa clinical testing laboratory in Orlando, Florida, and supports discovery-stage researchers worldwide with advanced kits and informatics. Learn more at www.arimagenomics.com and www.aventatest.com, and follow us on LinkedIn and X.

View source version on businesswire.com:https://www.businesswire.com/news/home/20250903750969/en/

CONTACT: Arima Genomics Media Contact:

Rachel Ford Hutman

[email protected]

+1.301.801.5540

KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA

INDUSTRY KEYWORD: GENETICS HEALTH ONCOLOGY MEDICAL DEVICES

SOURCE: Arima Genomics, Inc.

Copyright Business Wire 2025.

PUB: 09/03/2025 07:58 AM/DISC: 09/03/2025 07:57 AM

http://www.businesswire.com/news/home/20250903750969/en